Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

176
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
176
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

235
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
235
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.1K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma Carboxylesterase 1 Predicts Methylphenidate Exposure: A Proof-of-Concept Study Using Plasma Protein Biomarker for Hepatic Drug Metabolism.

Clinical pharmacology and therapeutics·2021
Same author

Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.

Pharmacotherapy·2018
Same author

The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder.

Journal of child and adolescent psychopharmacology·2017
Same author

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Journal of clinical psychopharmacology·2017
Same author

Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Journal of clinical psychopharmacology·2015

Related Experiment Video

Updated: Mar 28, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

14.4K

Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Kennerly S Patrick1, Arthur B Straughn2

  • 1Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC (K.S.P.); and Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, Tennessee (A.B.S.) patrickk@musc.edu.

Drug Metabolism and Disposition: the Biological Fate of Chemicals
|January 6, 2016
PubMed
Summary

This study found that while dl-methylphenidate (dl-MPH) and dexmethylphenidate (d-MPH) are bioequivalent, d-MPH provides greater early exposure. This difference may impact ADHD treatment individualization.

More Related Videos

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

17.0K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K

Related Experiment Videos

Last Updated: Mar 28, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

14.4K
Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

17.0K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K

Area of Science:

  • Pharmacology
  • Pharmacokinetics
  • Neuroscience

Background:

  • Methylphenidate is a central nervous system stimulant used to treat ADHD.
  • dl-Methylphenidate (dl-MPH) is a racemic mixture, while dexmethylphenidate (d-MPH) is the enantiopure active isomer.
  • Understanding the pharmacokinetic differences between dl-MPH and d-MPH is crucial for optimizing ADHD treatment.

Purpose of the Study:

  • To compare the pharmacokinetic profiles of immediate-release dl-methylphenidate (IR dl-MPH) and immediate-release dexmethylphenidate (IR d-MPH).
  • To evaluate the bioequivalence of d-methylphenidate exposure from both formulations.
  • To assess the clinical implications of differing early exposure profiles.

Main Methods:

  • A randomized, crossover study design was employed.
  • Twelve men and twelve women received IR dl-MPH (0.3 mg/kg) or IR d-MPH (0.15 mg/kg).
  • Plasma concentrations of d-MPH were measured, with a focus on partial area under the curve (pAUC0-3 h) as a novel regulatory metric.

Main Results:

  • Both IR dl-MPH and IR d-MPH demonstrated bioequivalence for d-MPH in terms of Cmax and AUC0-∞.
  • However, IR d-MPH showed significantly greater early exposure (pAUC0-3 h) to d-MPH compared to IR dl-MPH.
  • Specifically, the 1-hour d-MPH concentration was 56% lower after IR dl-MPH than after IR d-MPH.

Conclusions:

  • Despite overall bioequivalence, the reduced early d-MPH exposure from dl-MPH highlights potential limitations of standard bioequivalence metrics.
  • The distinct early exposure profiles suggest that d-MPH may offer advantages for rapid symptom control in ADHD.
  • This knowledge can aid in the individualization and optimization of methylphenidate therapy for ADHD patients.